<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Phentolamine (ophthalmic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Phentolamine (ophthalmic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Phentolamine (ophthalmic): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="142989" href="/d/html/142989.html" rel="external">see "Phentolamine (ophthalmic): Drug information"</a> and <a class="drug drug_patient" data-topicid="142999" href="/d/html/142999.html" rel="external">see "Phentolamine (ophthalmic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F58721330"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Alpha-Adrenergic Blocking Agent, Ophthalmic</span>;</li>
<li>
<span class="list-set-name">Ophthalmic Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F58801510"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6bd91393-4747-4cd3-88bf-a0319358dee2">Mydriasis, pharmacologically induced; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mydriasis, pharmacologically induced; treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Not recommended for use when active ocular inflammation is present.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥3 to &lt;12 years: Ophthalmic: Instill 1 drop in dilated eye(s) once following completion of ophthalmic examination or procedure.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Ophthalmic: Instill 1 to 2 drop(s) in dilated eye(s) once following completion of ophthalmic examination or procedure. If 2 drops are to be instilled, wait 5 minutes between each drop.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F58801511"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F58801512"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F58801269"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="142989" href="/d/html/142989.html" rel="external">see "Phentolamine (ophthalmic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aa8fa48f-6ba2-47d9-a1af-367510029108">Mydriasis, pharmacologically induced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mydriasis, pharmacologically induced:</b>
<b>Ophthalmic:</b> Instill 1 or 2 drops into each dilated eye following the completion of the eye exam or procedure; when using 2 drops, instill second drop 5 minutes after the first drop.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F58801271"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F58801272"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F58749289"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Ophthalmic: Conjunctival hyperemia (12%), eye discomfort (instillation site: 16%; including burning sensation of eyes, eye pain, and stinging of eyes)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Gastrointestinal: Dysgeusia (6%)</p></div>
<div class="block coi drugH1Div" id="F58709336"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F58801257"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular inflammation: Use is not recommended when iritis is present; adhesions may form between the iris and the lens.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Contact lens wearers: Remove contacts prior to administration and wait at least 10 minutes before reinserting.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For ophthalmic use only. To avoid contamination, do not touch tip of container to any surface.</p></div>
<div class="block prod-avail drugH1Div" id="F58709331"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Ryzumvi: FDA approved September 2023; availability anticipated in 2024.</p></div>
<div class="block admp drugH1Div" id="F58801513"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Ophthalmic: For topical ophthalmic use only; not for injection. Single-use vial may be used for both eyes if necessary. Remove contact lenses prior to instillation. Wash hands before and after application. To avoid contamination, do not touch vial tip to eye or other surfaces. If 2 drops are necessary for dose, wait 5 minutes before administering second drop. Wait at least 10 minutes after administration before reinserting contact lenses. Discard vial immediately after use.</p></div>
<div class="block adm drugH1Div" id="F58801273"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Ophthalmic:</b> For ophthalmic use only. Administer into dilated eye(s) after the completion of eye exam or procedure. Single-patient use vial may be used to dose both dilated eyes; discard immediately after use. Remove contact lenses prior to instillation and wait 10 minutes before reinserting. Do not touch the tip of the dropper to the eye, fingertips, or other surface.</p></div>
<div class="block sts drugH1Div" id="F58801263"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store refrigerated at 2°C to 8°C (36°F to 46°F); protect from freezing. Upon opening the foil pouch, may store at 20°C to 25°C (68°F to 77ºF) for up to 14 days. Discard opened single-dose vials immediately after use.</p></div>
<div class="block usep drugH1Div" id="F58721328"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of pharmacologically induced mydriasis produced by adrenergic agonists (eg, phenylephrine) or parasympatholytic (eg, tropicamide) agents (FDA approved in ages ≥3 years and adults).</p></div>
<div class="block cyt drugH1Div" id="F58739444"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F58739441"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F58801255"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Animal reproduction studies were not conducted following ophthalmic application.</p>
<p style="text-indent:0em;margin-top:2em;">If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctual occlusion to decrease potential exposure to the fetus (Samples 1988).</p></div>
<div class="block pha drugH1Div" id="F58801264"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Phentolamine is a relatively nonselective alpha-1 and alpha-2 adrenergic antagonist. Phentolamine reversibly binds to alpha-1 adrenergic receptors on the iris dilator muscle, thereby reducing pupil diameter. Phentolamine directly antagonizes the mydriatic effect of an alpha-1 adrenergic agonist, and indirectly reverses mydriasis induced by muscarinic antagonist effects on the iris sphincter muscle.</p></div>
<div class="block phk drugH1Div" id="F58801265"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Within 30 minutes; maximum effect: 60 to 90 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 15 to 60 minutes.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Ryzumvi.1">
<a name="Ryzumvi.1"></a>Ryzumvi (phentolamine) [prescribing information]. Farmington Hills, MI: Ocuphire Pharma Inc; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2903673">
<a name="2903673"></a>Samples JR, Meyer SM. Use of ophthalmic medications in pregnant and nursing women. <i>Am J Ophthalmol</i>. 1988;106(5):616-623.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-ophthalmic-pediatric-drug-information/abstract-text/2903673/pubmed" id="2903673" target="_blank">2903673</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 142991 Version 5.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
